Cervomed Inc (CRVO)

$6.58 -0.06 (-0.90%)
Market Cap 61.44M
Revenue (ttm) 9.74M
Net Income (ttm) -16.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -167.25%
Debt to Equity Ratio 0.00
Volume 67,700
Avg Vol 68,326
Day's Range N/A - N/A
Shares Out 9.25M
Stochastic %K 13%
Beta -0.89
Analysts Strong Sell
Price Target $22.43

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 744 4400
Address:
20 Park Plaza, Suite 424, Boston, United States
Doom_Gloom_AR
Doom_Gloom_AR Jan. 23 at 4:34 AM
$CRVO Let me know when it's time to wake up John Alam. While we are in this waiting period, the chairman of our board Josh Boger who owns around 10% of the company was the subject of a compelling book https://www.amazon.com/Billion-Dollar-Molecule-Companys-Perfect/dp/0671510576 A strong read for these boring times. In any event. I almost never hold stocks through doldrums like this unless I'm FULLY CONVINCED that it will eventually be successful. I reserve 3% of port for you CRVO. I fully intend to increase that position to my personal investing rule that I shall not invest more then 100% of port in any one stock. Therefore I shall invest 100% of port in this stock, but like any caterpillar in it's cocoon the time is not here yet. The money must be shown to get there and I don't see the money yet. The dilution risk is too high. Interesting that they have not pulled the trigger on toxic 2x or 3x warrant coverage financing from shit funds. For this I thank management [imux, xlo are example]. It's nice when management has skin in this game.
1 · Reply
Stock__Hunter
Stock__Hunter Jan. 23 at 3:47 AM
$CRVO pattern now bag holder. be at train station early
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 22 at 7:03 PM
$CRVO these bots are embarrassing Awful board /stock
1 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 22 at 4:25 PM
$CRVO buying lower ..always ..great
0 · Reply
Lizardbronsen
Lizardbronsen Jan. 22 at 3:04 PM
$CRVO
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 22 at 2:40 PM
$CRVO merdomed a mediocrity stock we know now
0 · Reply
Doki0926
Doki0926 Jan. 22 at 1:28 PM
$CRVO when will be a cata pult?
1 · Reply
Doki0926
Doki0926 Jan. 22 at 10:26 AM
$CRVO WTF❓❓❓
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 22 at 8:16 AM
$CRVO poor people Poor board Mediocre innovative bio stock
0 · Reply
Pharoh42
Pharoh42 Jan. 21 at 9:47 PM
$CRVO What the actual fuck
0 · Reply
Latest News on CRVO
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 4, 2025, 5:00 PM EST - 7 weeks ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Dec 2, 2025, 7:00 AM EST - 7 weeks ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 24, 2025, 7:00 AM EST - 2 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

CervoMed to Present at the Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 3 months ago

CervoMed to Present at the Emerging Growth Conference

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 11:54 AM EDT - 3 months ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 8, 2025, 7:00 AM EDT - 3 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 2, 2025, 8:00 AM EDT - 4 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 17, 2025, 7:30 AM EDT - 4 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

CervoMed to Participate in Upcoming Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 5 months ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 11:20 AM EDT - 6 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 28, 2025, 7:00 AM EDT - 6 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

Jul 8, 2025, 7:00 AM EDT - 7 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 12, 2025, 8:00 AM EDT - 9 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Mar 31, 2025, 2:34 PM EDT - 10 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 25, 2025, 8:00 AM EDT - 10 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 22, 2025, 2:55 AM EDT - 10 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Mar 10, 2025, 4:05 PM EDT - 11 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 2, 2024, 2:59 AM EDT - 1 year ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Apr 1, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 28, 2024, 8:30 AM EDT - 1 year ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Mar 5, 2024, 8:00 AM EST - 2 years ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 12, 2024, 8:00 AM EST - 2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 7, 2024, 8:30 AM EST - 2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

CervoMed to Participate in the Emerging Growth Conference 67

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

CervoMed to Participate in the Emerging Growth Conference 66

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Doom_Gloom_AR
Doom_Gloom_AR Jan. 23 at 4:34 AM
$CRVO Let me know when it's time to wake up John Alam. While we are in this waiting period, the chairman of our board Josh Boger who owns around 10% of the company was the subject of a compelling book https://www.amazon.com/Billion-Dollar-Molecule-Companys-Perfect/dp/0671510576 A strong read for these boring times. In any event. I almost never hold stocks through doldrums like this unless I'm FULLY CONVINCED that it will eventually be successful. I reserve 3% of port for you CRVO. I fully intend to increase that position to my personal investing rule that I shall not invest more then 100% of port in any one stock. Therefore I shall invest 100% of port in this stock, but like any caterpillar in it's cocoon the time is not here yet. The money must be shown to get there and I don't see the money yet. The dilution risk is too high. Interesting that they have not pulled the trigger on toxic 2x or 3x warrant coverage financing from shit funds. For this I thank management [imux, xlo are example]. It's nice when management has skin in this game.
1 · Reply
Stock__Hunter
Stock__Hunter Jan. 23 at 3:47 AM
$CRVO pattern now bag holder. be at train station early
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 22 at 7:03 PM
$CRVO these bots are embarrassing Awful board /stock
1 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 22 at 4:25 PM
$CRVO buying lower ..always ..great
0 · Reply
Lizardbronsen
Lizardbronsen Jan. 22 at 3:04 PM
$CRVO
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 22 at 2:40 PM
$CRVO merdomed a mediocrity stock we know now
0 · Reply
Doki0926
Doki0926 Jan. 22 at 1:28 PM
$CRVO when will be a cata pult?
1 · Reply
Doki0926
Doki0926 Jan. 22 at 10:26 AM
$CRVO WTF❓❓❓
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 22 at 8:16 AM
$CRVO poor people Poor board Mediocre innovative bio stock
0 · Reply
Pharoh42
Pharoh42 Jan. 21 at 9:47 PM
$CRVO What the actual fuck
0 · Reply
MV0527
MV0527 Jan. 21 at 9:24 PM
$CRVO Alam, WTF. Start doing your job as a freaking CEO. Investors should also be a priority. You're like Cobuzzi was. SCHMUCK
1 · Reply
Disinformation_Consumer
Disinformation_Consumer Jan. 21 at 8:55 PM
$CRVO Trump chickened out, now here’s the part where CRVO gets left behind.
0 · Reply
BPler
BPler Jan. 21 at 5:44 PM
$SPY Same pattern for years, when it goes most invested people don't sell because it seems to low, and who can or new people to add. Over time the market beats, and with companies with $CRVO (biotech growth before Phase 3) or $CXM (profitable, but less growth) it is always an super add situation. You can always invest, if you play the long game and have a solid DD, and tbh trumps is gifting you dips to buy.
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 21 at 5:19 PM
$CRVO these are awful One of the worst bio stock and board that I have seen
0 · Reply
Stu_padasso
Stu_padasso Jan. 21 at 5:16 PM
$CRVO fucking garbage all of the bluster and price targets were horse shit even the insder purchases i suspect were for 2026 tax right offs give the illusion of something big coming which there is but it is going to knock the price down under 2 eventually
0 · Reply
Scorpole
Scorpole Jan. 21 at 4:40 PM
$CRVO looks like that they have already reached out to some people to see if an offering is possible
1 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 21 at 4:31 PM
$CRVO 🤡 go home
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jan. 21 at 4:17 PM
$CRVO with these sh 🫣its The only way is bankruptcy Dilutions and thi eves ….
0 · Reply
Ghostofgreg1
Ghostofgreg1 Jan. 21 at 2:33 PM
$CRVO Whats todays excuse? Market conditions? Cat ate my homework? The weather? F in shite show
3 · Reply
Stu_padasso
Stu_padasso Jan. 20 at 3:19 PM
$CRVO going to be a rough day here based on markets in general this is toast
1 · Reply
Orlandotrader
Orlandotrader Jan. 19 at 8:58 PM
$CRVO Based on its current operating plan, CervoMed believes its cash, cash equivalents, and marketable securities on hand as of September 30, 2025, will enable the Company to fund its planned operating expenses and capital expenditure requirements into the third quarter of 2026. Tic Toc Tic Toc Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia (FTD) and topline results from Phase 2a trial in recovery after stroke expected in 2026 We waiting for this before the Raise?
1 · Reply
Orlandotrader
Orlandotrader Jan. 18 at 2:09 PM
$CRVO Compelling Opportunity but cash at 26 Million to last till Third Quarterof 2026. Phase 3 to start second Half of 2026. Obvious Cash raise coming soon. This will Crater. Wait for the Raise and will start to accumulate.
1 · Reply